We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Insurers, Advocacy Groups Urge FDA to Finalize Biosimilar Guidance
Insurers, Advocacy Groups Urge FDA to Finalize Biosimilar Guidance
A coalition of health care stakeholders called on the FDA to issue final guidance on interchangeable biosimilars to help promote drug price competition, saying the agency’s failure to finalize its January 2017 draft guidance created “significant uncertainty.”